Continuing Education for Hematology | Online CME Hematology Courses

Page 2 of 2

Results 76 - 102 of 102

How to Treat iTTP in 2020

TTP: Complexities and Comorbidities

Monitoring of Immnune Mediated TTP

Diagnosis of TTP

Key Considerations: Advances in Gene Therapy for Hemophilia

Integrating Emerging Treatments for Hemophilia A

Gene Therapy for Treatment of Hemophilia: An Introduction to AAV Vector Gene Transfer

Gene Therapy for Treatment of Hemophilia: Other Strategies and Targets

9915-conf_covg_icon_263x149

Conference Coverage from ISTH 2019 in Melbourne

A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy

Gene Therapy for Treatment of Hemophilia: Common Concerns in Gene Therapy

A History of Hemophilia Treatment: Factor Replacement to Gene Therapy

Getting to Know Gene Therapy: Terminology and Concepts

Biosimilars: Applying the Science to Hematology/Oncology Practice

biosims-archmed icon

Top Questions about Biosimilars in Hematology/Oncology

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics

Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?

Pharmacovigilance and Biosimilars: Any Special Considerations?

Interchangeability and Biosimilars: What will this Mean for Clinical Practice?

Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?

Biosimilars: As Safe and Effective as the Reference Product?

Drift and the Manufacturing of Biologics: What is it and Does it Matter?

Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Page 2 of 2

The France Foundation

A ACCME Accredited provider.

The France Foundation ©

10 Vista Drive, Old Lyme, CT USA